Immunomedics (IMMU) was Upgraded by Jefferies to ” Buy”. Earlier the firm had a rating of “Hold ” on the company shares. Jefferies advised their investors in a research report released on May 6, 2016.
Immunomedics closed down -0.01 points or -0.27% at $3.74 with 15,21,564 shares getting traded on Wednesday. Post opening the session at $3.7, the shares hit an intraday low of $3.54 and an intraday high of $3.77 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on Dec 14, 2015, Don C Stark (director) sold 5,100 shares at $3.15 per share price. According to the SEC, on Jun 16, 2015, Cynthia L Goldenberg (President and CEO) sold 210,991 shares at $4.09 per share price. On Jun 16, 2015, David M Goldenberg (CSO & Chairman of the BOD) sold 210,991 shares at $4.09 per share price, according to the Form-4 filing with the securities and exchange commission.
Immunomedics Inc. is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer autoimmune disorders and other serious diseases. The Company’s technologies allow it to create humanized antibodies in unlabeled or naked form or conjugated with radioactive isotopes chemotherapeutics cytokines or toxins. Its product candidates include 90Y-clivatuzumab tetraxetan. Its radiolabeled antibody is in a Phase III registration trial in patients with advanced pancreatic cancer. Its portfolio of investigational products also includes antibody-drug conjugates (ADCs). Its ADCs consist of sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130) which are in Phase II trials for a number of solid tumors and metastatic colorectal cancer (mCRC) respectively. It has other product candidates that target solid tumors and hematologic malignancies as well as other diseases in clinical and pre-clinical development-stages.